Intra-Cellular Therapies Q2 2024 GAAP EPS $(0.16) Beats $(0.20) Estimate, Sales $161.400M Beat $157.880M Estimate
Author: Benzinga Newsdesk | August 07, 2024 07:31am
Intra-Cellular Therapies (NASDAQ:
ITCI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. The company reported quarterly sales of $161.400 million which beat the analyst consensus estimate of $157.880 million by 2.23 percent. This is a 45.68 percent increase over sales of $110.792 million the same period last year.
Posted In: ITCI